Article

VisionCare granted postponement of FDA review of implantable telescope for AMD

Rockville, MD-The FDA has postponed a review of an investigational prosthetic device for the treatment of age-related macular degeneration (AMD) at the request of its developer, VisionCare Ophthalmic Technologies Inc., so that the company can submit additional long-term clinical data.

Rockville, MD-The FDA has postponed a review of an investigational prosthetic device for the treatment of age-related macular degeneration (AMD) at the request of its developer, VisionCare Ophthalmic Technologies Inc., so that the company can submit additional long-term clinical data. The hearing for the device (Implantable Miniature Telescope) had been scheduled for April 24.

“VisionCare will be submitting additional data to [the] FDA that we believe will be helpful in completing the review and regulatory approval determination regarding the company's pre-market approval [PMA] application for our implantable telescope,” said Allen W. Hill, chief executive officer of VisionCare, based in Saratoga, CA. “We will work closely with [the] FDA on rescheduling the panel meeting and review of the regulatory application.”

The device, invented by Isaac Lipshitz, MD, is designed to be a solution for moderate to profound vision loss due to advanced, end-stage forms of AMD that have no current surgical or medical treatment options. Smaller than a pea, the telescope is implanted in one eye in an outpatient surgical procedure. In that eye, the device renders enlarged central vision images over a wide area of the retina to improve central vision; the non-operated eye provides peripheral vision for mobility and orientation.

After PMA application submission and a July 2006 FDA Ophthalmic Devices Advisory Panel meeting, the FDA issued a letter to VisionCare citing deficiencies in its application that must be addressed before regulatory approval. The issues primarily relate to corneal endothelial cell density and whether cataract removal in patients has a meaningful effect on improvement in visual acuity. In 2007, the company submitted PMA amendments to address the matters identified in the deficiency letter and also responded to additional questions from the FDA.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.